Publications tagged: Schizophrenia
Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer’s disease.
Bilderbeck AC, Penninx BWJH, Arango C, van der Wee N, Kahn R, Winter-van Rossum I, Hayen A, Kas MJ, Post A, Dawson GR. (2019). Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer’s disease. Neuroscience and Biobehavioral Reviews 97:87-93.
Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies.
Koychev, I., Joyce, D., Barkus, E., Ettinger, U., Schmechtig, A., Dourish, C.T., Dawson, G.R., Craig, K.J. and Deakin, J.F.W. (2016). Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies. Translational Psychiatry, May 17 [Epub ahead of print].
Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy. Program No. 886.18/VV11. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010
Schmechtig, A., Dourish, C.T., Craig, K.J., Dawson, G.R., Williams, S.C.R., Deakin, J.F.W., Lees, J., Wilkinson, L. and Ettinger U. (2010).
The neural correlates of allocentric spatial memory performance across the schizotypal personality spectrum. Program No. 886.19/VV12. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010
McMullen, K., Barkus, E., Daly, O.G.O., Kumari, V., Dawson, G.R., Dourish, C.T., Craig, K.J., Williams, S.C.R. and Morris, R.G. (2010).
Effects of high schizotypy on control of eye movements: modulation by antipsychotic drugs and nicotine. 49th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL: ACNP, 2010
Deakin, J.F.W., Schmechtig, A., Dourish, C.T., Craig, K.J., Dawson, G.R., Williams, S.C.R., Lees, J., Wilkinson, L. and Ettinger U. (2010).
A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-centre double-blind placebo-controlled study. European Neuropsychopharmacology, Jul;22(7):469-81.
Koychev, I., McMullen, K., Lees, J., Dadhiwala, R., Grayson, L., Perry, C., Schmechtig, A., Walters, J., Craig, K.J., Dawson, G.R., Dourish, C.T., Ettinger, U., Wilkinson, L., Williams, S.C.R., Deakin, J.F.W. and Barkus, E. (2011).
Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology Epub 2013 February 22.
Schmechtig A., Lees J., Grayson L., Craig K. J., Dadhiwala R., Dawson G.R., Deakin J.F.W., Dourish C.T., Koychev I, McMullen K, Migo E.M., Perry C., Wilkinson L., Morris R., Williams S.C.R., Ettinger U. (2013).
The effects of ketamine and risperidone on eye movement control in healthy volunteers. Translational Psychiatry, Dec 10;3:e334.
Schmechtig A., Lees J., Perkins A., Altavilla A., Craig K.J., Dawson G.R., Deakin J.F.William, Dourish C.T., Evans L.H., Koychev I., Weaver K., Smallman R., Walters J., Wilkinson L.S., Morris R., Williams S.C.R. and Ettinger U. (2013).
Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia. Biomarkers in Medicine, 8, 5-8.
Dourish, C.T. and Dawson, G.R. (2014).